MASSACHUSETTS MEDICAL SOCIETY HOUSE OF DELEGATES (I-16)

REFERENCE COMMITTEE A Public Health

Item #	Title	Code	Action	Page
1	Climate Change: What Can We Do About It?	CEOH/BOT Report I-16 A-1 [I-15 A-106]	Adopt	1
2	Epinephrine Auto-Injectors in Schools and Individualized Health Care Plans	Resolution I-16 A-101	Adopt	3
3	Appropriate Placement of Transgender Prisoners	CLGBT Report I-16 A-2 [I-15 B-2]	Adopt	5
4	Medical Aid-in-Dying Survey	Resolution I-16 A-102	Adopt as Amended	6
5	Family Leave for Early Child Care	Resolution I-16 A-103	Adopt as Amended	7
6	Sports-Related Concussions	Resolution I-16 A-104	Adopt as Amended	8
7	Sugar Consumption for Children	Resolution I-16 A-105	Adopt as Amended	10
8	Neurotoxin Exposure in Pregnant Women and Children	Resolution I-16 A-106	Not Adopt	11
9	Family Bill of Rights	Resolution I-16 A-107	Adopt as Amended	12
10	Core Values	Resolution I-16 A-108	Adopt	13
11	Education and Advocacy after Marijuana Legalization in Massachusetts	CPH Report I-16 A-3	Adopt	14

1 2 3 4 5 6 7 8	Co Tit	m #: de: le: onsors:		1 CEOH/BOT Report I-16 A-1 [I-15 A-106] Climate Change: What Can We Do About It? Committee on Environmental and Occupational Health Heather Alker, MD, Chair Board of Trustees James Gessner, MD, Chair
9 10 11	Re	port His	story:	Resolution I-15 A-106 Original Sponsor: Ihor Bilyk, MD
12 13	Re	comme	ndation:	
14 15 16 17	COI	ntained		ce committee recommends that the recommendations port I-16 A-1 [I-15 A-106] be adopted and the remainder
18 19		at the N e follow		edical Society adopt in lieu of Resolution I-15, A-106,
20 21 22 23	1.		he Massachusetts can Medical Asso	Medical Society adopt the following adapted from ciation policy:
23 24 25 26 27 28 29 30 31 32 33		a)	Climate Change' climate system is greenhouse gase changes have ha that "climate cha natural and hum and are generally	rs with the findings of the Intergovernmental Panel on s fifth assessment report that "human influence on the s clear, and recent anthropogenic emissions of es are the highest in history"; that "recent climate ad widespread impacts on human and natural systems"; ange will amplify existing risks and create new risks for an systems"; and "that risks are unevenly distributed y greater for disadvantaged people and communities in evels of development." <i>(HP)</i>
33 34 35 36 37 38		b)	policymaking at efforts to search	izes the importance of physician involvement in the state, national, and global levels and supports for novel, comprehensive, and economically sensitive itigating climate change to protect human health. <i>(HP)</i>
39 40 41		c)		rages physicians to consider and promote responsible policies and practices in the health care
42 43 44 45	2.	an app	-	ue a suitable way to invest a portion of its Portfolio in ve ("clean") energy fund and report back on progress at I-17. <i>(D)</i>

That the MMS consider and report back on a shift of non-pension investments into socially-responsible investments. (D)

~		
3		Itama 2.8.2; One Time Evenance of \$25,000
4	Fiscal Note:	Items 2 & 3: One-Time Expense of \$25,000
5	(Out-of-Pocket Expenses)	
6	FTF.	Eviating Otaff
7	FTE:	Existing Staff
8	(Staff Effort to Complete Project)	
9	·· · · · · · ·	
10		online and in-person testimony on this report.
11		e recommendation to adopt policy on climate
12	change, and to explore possibilities for soc	
13		nise that climate change is related to human
14		sus in the scientific community is that there is
15	, , ,	climate change, and between climate change
16		er noted the large body of evidence linking air
17	pollution to adverse human health effects,	
18	energy investments. Testimony addressed	
19		opulations, including children. Several testified
20	to the importance of adding the voice of me	edicine to this issue, which has health and
21	public health implications.	
22		
23	Other limited testimony opposed the recon	nmendations related to MMS's investment
24	practices, citing challenges identifying truly	"clean" energy investments and concerns "
25	about the effectiveness of this strategy in c	combatting climate change. However, the
26	majority of the testimony supported the rec	commendations, which are solely to explore
27	appropriate investment options which are l	both socially and fiscally responsible.
28		
29	House Vote:	

1	Item	#:	2
2	Code	ż.	Resolution I-16 A-101
3	Title:		Epinephrine Auto-Injectors in Schools and Individualized
4	THUC.		Health Care Plans
	~		
5	Spor	isors:	B. Dale Magee, MD
6			Lloyd Fisher, MD
7			MA Chapter of the American Academy of Pediatrics
8			DeWayne Pursley, MD, President
			Bewayne r disley, MB, r resident
9 10	Reco	ommendation:	
11			
12	Miste	er speaker, your referend	ce committee recommends that Resolution I-16 A-101 be
13	adop	oted.	
14	•		
15	1	RESOLVED That the	MMS support schools using their own emergency
	••		
16			auto-injectors instead of requiring parents to purchase
17			pinephrine auto-injectors for each child and that each
18		student and employee	who has life-threatening allergies be required to
19			ed school with an individualized health care plan; and,
20		be it further (HP)	······································
21			
	•		
22	2.		MMS encourage school districts to adopt as policy use
23		of their own emergend	cy supply of epinephrine auto-injectors instead of
24		requiring parents to p	urchase individually labeled epinephrine auto-injectors
25			t each student and employee who has life-threatening
26		•	be required to provide their designated school with an
27		individualized health of	care plan; and, be it further <i>(D)</i>
28			
29	3.	RESOLVED , That the	MMS communicate its policy regarding support for
30		school-supplied epine	ephrine auto-injectors and the requirement for
31			care plans for both students and employees to
32			usetts organizations, including the Massachusetts
33			Committees, the Massachusetts Association of School
34		Superintendents, and	the Massachusetts School Nurse Association. (D)
35			
36	Fisca	al Note:	No Significant Impact
37	(Out-	of-Pocket Expenses)	5
38	(Out		
	стс.		Eviating Ctaff
39	FTE:		Existing Staff
40	(Staf	f Effort to Complete Proj	ect)
41			
42	Your	reference committee he	ard thorough testimony in person and online in support of
43			estimony emphasized the role this policy could play in
44			
		•	high costs for patients who are required to purchase
45			r storage at schools, especially since many expire annually
46	witho	out being used. Concern	s were raised that this policy could expose schools to
47	liabili	ity, though others pointe	d out that schools already purchase and store epinephrine
48			First allergic reactions at school. A question was raised as to
49			ning for school nurses would be required; this policy would
50			s. Another individual suggested that the policy should cover
51	cam	os and pre-schools as w	ell; however, those entities fall under a different regulatory
	-		

- framework which would require additional investigation. Ultimately your reference committee recommends adoption of this resolution. 1 2 3 4
- House Vote: _____

1 2 3 4 5	Item # Code: Title: Spons		3 CLGBT Report I-16 A-2 [I-15 B-2] Appropriate Placement of Transgender Prisoners Committee on LGBT Matters Marian Craighill, MD, Chair
6 7 8 9	Report	History:	CLGBT Report I-15 B-2 Original Sponsor: Committee on LGBT Matters
10 11	Recom	mendation:	
12 13 14 15	contair		ce committee recommends that the recommendations -16 A-2 [I-15 B-2] be adopted and the remainder of the
16 17 18		he Massachusetts Me s follows:	edical Society adopt as amended Resolution I-15 B-2, to
19 20 21 22 23	1.	should be allowed to	etts Medical Society affirms that transgender prisoners b be placed in facilities that are reflective of their ntity regardless of surgical status, if they so choose.
24 25 26 27	2.		ate to the AMA for policy supporting the ability of ers to choose to be placed in facilities that are reflective oder status. <i>(D)</i>
28 29 30	Fiscal (Out-o	Note: f-Pocket Expenses)	No Significant Impact
31 32 33	FTE: (Staff I	Effort to Complete Proj	Existing Staff ect)
34 35 36 37 38 39 40 41	indicat regula emotic genera noted	ed that the recomment tions are not always fo anal health effects on tr al population, including	eard only favorable testimony on this report. Testimony dations are in line with federal regulations, but that those llowed. Testimony discussed the negative physical and ransgender individuals in prison, as compared to the increased rates of assault and depression. Testimony also ransgender person's choice in placement, as reflected in
42	House	Vote:	

1	Item #:	4
2	Code:	Resolution I-16 A-102
3	Title:	Medical Aid-in-Dying Survey
4	Sponsors:	Eric Ruby, MD
5	•	Carl Brownsberger, MD
6		
7	Recommendation:	
8		
9	Mister speaker, your reference	ce committee recommends that Resolution I-16 A-102 be
10		dition and deletion to read as follows:
11		
12	RESOLVED , That MMS con	duct a membership survey to determine physicians'
13		physicians-in-training in Massachusetts toward
14	medical aid-in-dying with a	report back to the MMS House of Delegates at A-17. (D)
15		
16	Fiscal Note:	One-Time Expense of \$10,000
17	(Out-of-Pocket Expenses)	
18		
19	FTE:	Existing Staff
20	(Staff Effort to Complete Proj	iect)
21		
22		eard online and in-person testimony largely in favor of this
23		to understand the will of the membership on this issue
24		Inter. Many testified to the importance of an unbiased,
25		nat the survey should be expanded to non-member
26		. Several also testified to including medical students and
27	other physicians in training.	
28		
29		resolution were opposed to physician assisted suicide, or
30		until after the referenced AMA study of the issue. Others
31		s-specific survey as legislation is being voted on at the state
32		vsicians in Massachusetts do not always coincide with
33		he country. Testimony noted the urgency of this issue, as
34		dying is expected in the next legislative session, and could
35	go to hearing in late Spring o	or Fall of 2017.
36		
37		commends an increased fiscal note to reflect the expanded
38		ling non-members and physicians in training, and to ensure
39		to complete a meaningful and timely survey and report
40	back to the HOD.	
41		
42	House Vote:	

1	Item #:	5
2	Code:	Resolution I-16 A-103
3	Title:	Family Leave for Early Child Care
4	Sponsor:	Michael Medlock, MD
5	•	,
6 7	Recommendation:	
8 9		nce committee recommends that Resolution I-16 A-103 be ddition and deletion to read as follows:
10 11 12		MMS support family leave with job protection and pay for vborns and infants, and, be it further <i>(HP)</i>
13 14 15 16		MMS support family leave policies that do not unduly ses, and, be it further <i>(HP)</i>
17 18 19 20		MMS work with other appropriate organizations and social and economic support for family leave to care for and, be it further <i>(D)</i>
21 22 23 24 25 26	legislative strategies ir developing MMS policy leave time to six mont	MMS investigate <u>research</u> specific state and federal in support of improved early child care, <u>with a view to</u> <u>y on this topic.</u> such as increasing the job protected hs, providing paid leave time for three months, and ons for unpaid child care by extended family members.
27 28	Fiscal Note:	No Significant Impact
29	(Out-of-Pocket Expenses)	No Significant Impact
30		
31	FTE:	Existing Staff
32	(Staff Effort to Complete Pro	•
33	(Stall Ellor to Complete Fit	Jeol)
34	Vour reference committee h	neard strong support for adopting policy to improve family
35		ns and infants. Testimony emphasized that public health
36		ciation between improving family leave policies and the
37	00	ness of babies and parents. Your reference committee
38		policy to address the concern that certain parental leave
39	5	atively impact small businesses, including small medical
40		hat listing specific policy examples in the final resolve could
40		ions to be considered, and instead suggested an open-
41		policies from other states and countries that could inform
42 43	more detailed MMS policy.	
43 44		
44	House Vote:	

1	Item #	: 6	3
2	Code:	F	Resolution I-16 A-104
3	Title:	S	Sports-Related Concussions
4	Spons	or: N	Aichael Medlock, MD
5	•		
6	Recom	nmendation:	
7			
8	Mister	speaker, your reference	committee recommends that Resolution I-16 A-104 be
9			ition and deletion to read as follows:
10	aaopt		
11	RESO	I VED That the Massa	chusetts Medical Society adopt the following adapted
12			American Medical Association and the American
13	•	ation of Neurological	
14	A3300		ourgeons.
15	1	That the MMS continu	ie te work:
16			anizations to increase athletic safety by promoting
17			vareness, including the fact that even mild cases of
18			· •
			n injury may have serious and prolonged
19		consequences	
20			anizations to develop a program of public education
21			iderscore the importance of prevention, diagnosis,
22			atment of concussion and other brain-related injuries
23			te state and specialty medical societies to enhance
24			for continuing medical education
25			overning bodies, as well as players, coaches and
26			, to ensure that an athlete who exhibits symptoms
27			h these types of injuries is properly evaluated,
28		-	eared before they are allowed to return and participate
29		in sports	
30	(D))	
31	-		
32	2.		t the adoption of evidence-based, age-specific
33			luation and management of concussion in all athletes
34			, other health professionals, and athletic
35		organizations. (HP)	
36	_		
37	3.		ts encourage research on sports-related concussions,
38		such as to:	
39			ninants of concussion
40			ort- and long-term consequences of repetitive head
41		impacts	
42			valuate risk-reduction measures
43			ge-sensitive biomarkers that will <u>methods to</u> improve
44			uracy, reduce the dependence on self-reporting, and
45		inform better g	juidelines <i>(HP)</i>
46			
47	Fiscal		No Significant Impact
48	(Out-o	f-Pocket Expenses)	
49			
50	FTE:		Existing Staff
51	(Staff I	Effort to Complete Proje	ct)

1 Your reference committee heard testimony largely in favor of this resolution. Testimony 2 indicated that comprehensive regulations from the Massachusetts Department of Public 3 Health concerning return to play after concussion are already in place, and that MMS is 4 already working on many of the directives; this resolution would serve to establish MMS 5 policy on the issue. 6 7 There was some testimony calling for the deletion of references to the American Medical 8 Association and the American Association of Neurological Surgeons, however the 9 resolved clauses are largely based on the policies and directives from these two 10 organizations and therefore they should be referenced. 11 12 Testimony also included concern that the term "supporting" in resolved 3 might be 13 interpreted by some to mean financial support; therefore the word "encourage" was used 14 to better define the intent of the author. It was also noted that damage-sensitive

- 15 biomarkers are only one known method to improve diagnostic accuracy, so that
- 16 language was also amended to include other methods.
- 17
- 18 House Vote: _____

1	Item #:	7
2	Code:	Resolution I-16 A-105
3	Title:	Sugar Consumption for Children
4	Sponsor:	Ihor Bilyk, MD
5	•	
6	Recommendation:	
7		
8	Mister speaker, your reference	ce committee recommends that Resolution I-16 A-105 be
9		bstitution to read as follows:
10		
11	RESOLVED , That the MMS	support, as part of a holistic approach to childhood
12	nutrition, limiting children's	s intake of sugar-sweetened beverages and overall
13	added sugar. <i>(HP)</i>	
14		
15	Fiscal Note:	No Significant Impact
16	(Out-of-Pocket Expenses)	
17		
18	FTE:	Existing Staff
19	(Staff Effort to Complete Proj	iect)
20		
21		eard in person and online testimony in support of the
22		t that it was too narrowly focused. There was strong
23		ving the language that referenced specific sugar limits for
24		amount is derived from a single study source. MMS has
25		ssing sugar consumption in adults as part of a well-
26	-	resolution should be substituted with a statement that
27	expands MMS's stance on si	ugar consumption limits to include children.
28		
29	House Vote:	

1	Item #:	8		
2	Code:	Resolution I-16 A-106		
3	Title:	Neurotoxin Exposure in Pregnant Women and Children		
4	Sponsor:	Ihor Bilyk, MD		
5		•		
6 7	Recommendation:			
8 9 10	Mister speaker, your referer not adopted.	nce committee recommends that Resolution I-16 A-106 be		
10 11 12 13 14	a proven toxic chemica	IMS supports the prevention of industry from replacing al with a similar untested agent that may have similarly n human health; and, be it further <i>(HP)</i>		
15 16 17 18	environmental chemic	IMS supports having the burden of proof for al safety shifted to more closely resemble how drugs are y has to be "proven first." <i>(HP)</i>		
10 19	Fiscal Note:	No Significant Impact		
20	(Out-of-Pocket Expenses)			
21	(••••••••••••••••••••••••••••••••			
22	FTE:	Existing Staff		
23	(Staff Effort to Complete Pro			
24	X I			
25	Your reference committee h	eard mixed testimony on this resolution, including testimony		
26		for amending the language. Online and in-person testimony		
27		topic and of the regulatory issues; discussed that the		
28		ising, or difficult to understand; and recommended referral to		
29		es. Other testimony reflected that the resolution lacked the		
30		termine whether this was within the purview of the MMS. In		
31		nt and effective use of MMS resources, your reference		
32	committee recommends this resolution be not adopted, but would encourage the			
33		sponsor to work with the relevant committees to identify concerns, references, and		
34	background that would support focused recommendations for the HOD to consider in the			
35	future.			
36				
37	House Vote:			

1	Item #:	9
2	Code:	Resolution I-16 A-107
3	Title:	Family Bill of Rights
4	Sponsor:	Ihor Bilyk, MD
5		
6	Recommendation:	
7		
8		ce committee recommends that Resolution I-16 A-107 be
9	adopted as amended by su	bstitution to read as follows:
10		
11	•	MS support the inclusion of feedback from Patient and
12	• •	ils in guiding hospitals as they deliver quality health
13	care. <i>(HP)</i>	
14		
15 16	Fiscal Note:	One-Time Expense of \$15,000
17	(Out-of-Pocket Expenses)	No Significant Impact
18	(Out-of-Pocket Expenses)	
19	FTE:	Existing Staff
20	(Staff Effort to Complete Proj	
20		
22	Your reference committee he	ard testimony largely in opposition to this resolution.
23		concerns that the definition of "family" can be problematic,
24		vant family members involved in their care, and/or may not
25		ne, as in domestic violence situations. Testimony also
26		volvement is an important consideration in all patient care
27		atients is always our primary role. The original second
28		impacted the primacy of patient autonomy, especially with
29	a nebulous definition of famil	
30		
31	Testimony noted that Patient	and Family Advisory Councils (PFACs) are already
32		ts Department of Public Health, but that at some hospitals,
33	they may not be sufficiently e	ffective. Your reference committee recommends this
34	substitute resolve to encoura	ge more meaningful use of PFACs.
35		
36	House Vote:	

1	Item #:	10
2	Code:	Resolution I-16 A-108
3	Title:	Core Values
4	Sponsor:	Barbara Herbert, MD, FASAM, DABAM
5		
6	Recommendation:	
7		
8	Mister speaker, your reference	ce committee recommends that Resolution I-16 A-108 be
9	adopted.	
10		
11	•	reaffirms its commitment to working for the best
12		ery person living in the Commonwealth regardless of
13		al or ethnic origin, sexual orientation, gender identity,
14	religious affiliation, disabil	ity, or economic status. <i>(HP)</i>
15		
16	Fiscal Note:	No Significant Impact
17	(Out-of-Pocket Expense)	
18		
19	FTE:	Existing Staff
20	(Staff Effort to Complete Pro	ject)
21		
22		eard overwhelmingly strong testimony in support of this
23		stifying indicated the resolution reflects the mission and
24		ical profession. There was strong support for adoption of this
25	resolution, and for continued	work on behalf of MMS to uphold these values.
26		
27	House Vote:	

1	Ite	m #:	11
2	Со	de:	CPH Report I-16 A-3
3	Tit	le:	Education and Advocacy after Marijuana Legalization in
4			Massachusetts
5	Sp	onsor:	Committee on Public Health
6			Steven Ringer, MD, Chair
7			
8 9	Re	commendation:	
10	Mis	ster speaker, vour referen	ce committee recommends that the recommendations
11			6 A-3 be adopted and the remainder of the report be
12	file		
13			
14	1.	That the MMS will activ	ely engage with state policymakers to advocate for
15			bry policies on legal marijuana that will protect the
16		• *	cluding policies that would:
17		-	ccess to marijuana
18			to conduct and publish research on the clinical and
19			fects of recreational marijuana
20			ion about the health effects of recreational marijuana
21			uality standards for recreational and medical marijuana
22		•	funding for health and public health interventions
23			ana, including research, abuse prevention education
24			and keep the HOD apprised through report back to the
25		HOD at A-17 and	1 I-1 <i>7</i>
26		(D)	
27	2	That the MMS exects a	recourse tool to help physiciane recoverd to the people
28 29	2.		resource tool to help physicians respond to the needs ay be using, or asking about, recreational or medical
29 30		marijuana. <i>(D)</i>	ay be using, or asking about, recreational or medical
30 31			
32	Fig	cal Note:	One-Time Expense of \$15,000
33		ut-of-Pocket Expenses)	
34	(0)		
35	FΤ	E:	Existing Staff
36		aff Effort to Complete Pro	0
37	(J
38	Yo	ur reference committee h	eard strong, unanimous support for the concept of MMS
39			ecreational and medical marijuana laws and regulations in
40			lic health. There was also support for creating a resource
41			ond to questions from patients about marijuana. Limited
42			but based on the preponderance of the testimony, your
43			mends to adopt as written.
44			
45	Ho	use Vote:	

Mister speaker, this concludes the report of Reference Committee A. My thanks to reference committee members Heidi Foley, MD, Ronald Newman, MD, Luis Sanchez, MD, Ann Spires, MD, Ludwik Szymanski, MD, and Simone Wildes, MD; staff coordinators Robyn Alie, Candace Savage and Karen Harrison; Brendan Abel, Esq., legal counsel; and all those who testified before the committee.

For the reference committee,

Kevin O'Callaghan, MD, Chair

REFERENCE COMMITTEE B Health Care Delivery

Item #	Title	Code	Action	Page
1	Protection of Provider-Patient Privilege	Resolution I-16 B-201	Adopt	1
2	A Resolution to Have the Retail Price of Drugs Displayed in Direct-to-Consumer	Resolution I-16 B-202	Adopt as Amended	2
3	Pharmaceutical Advertising Expansion of MassPAT to Enhance the Medication Reconciliation Process	Resolution I-16 B-203	Not Adopt	3
4	Proposal to End the Federal Certification of EHRs Program	CIT Report I-16 B-1	Adopt as Amended	4
5	Telemedicine Reimbursement	COL Report I-16 B-2 [A-16 B-202]	Adopt as Amended	6
6	Reimbursement for Physician Oversight in Incident to Billing	CSPP Report I-16 B-3	Refer to the BOT for Report Back at A- 17	7
7	Third-Party Payers Contracted Fee Schedule Should Be Based on at Least 100 Percent of the Current and Geographically Appropriate Medicare Fee Schedule at Time of Contracting	Resolution I-16 B-204	Adopt as Amended	8
8	Timely Response by the Third-Party Payer to the Request for Fee Schedule From Participating Practices	Resolution I-16 B-205	Adopt	9
9	Adding Transparency and Responsiveness to Denied Claims Appeals	Resolution I-16 B-206	Adopt as Amended	10
10	Independent Surgi-centers Are Safe and Cost Effective	Resolution I-16 B-207	Refer to the BOT for Report Back at I-17	11

11	Addressing Discriminatory Health Plan Exclusions or Problematic Benefit Substitutions for Essential Health Benefits under the Affordable Care Act	CWM Report I-16 B-4	Adopt as Amended	12
12	Support for Deferred Action for Childhood Arrivals (DACA)-Eligible Health Care Professionals, Current and in Training	Resolution I-16 B-208	Adopt as Amended	13

1	Item #:	1
2	Code:	Resolution I-16 B-201
3	Title:	Protection of Provider-Patient Privilege
4	Sponsor:	Marguerite Youngren
5		
6 7	Recommendation:	
8	Mister speaker, vour reference	ce committee recommends that Resolution I-16 B-201 be
9	adopted.	
10	-	
11		advocate to the relevant state and local bodies, and
12		cate to the relevant national bodies, for the provider-
13 14		lated according to the privacy protections in the Health Accountability Act of 1996 without regard to where care
15	is received. (D)	accountability Act of 1990 without regard to where care
16		
17	Fiscal Note:	No Significant Impact
18	(Out-of-Pocket Expenses)	
19		
20	FTE:	Existing Staff
21 22	(Staff Effort to Complete Proj	ect)
22 23	Your reference committee co	onsidered testimony provided both in person and online.
24		prtive of this resolution however, some testimony suggested
25		vith "physician-patient". The committee discussed this point
26		nony provided by both the resolution sponsor and others
27		should apply to all settings of health care delivery, including
28	-	bvided by non-physicians, such as school-based therapy.
29		mmittee, while appreciative of the desire to preserve
30		elt that in this particular instance, keeping the term broader
31		nake sense with the goal of preserving the protected health
32	· ·	dless of the setting or provider of care.
33		
34	House Vote:	

1	Iter	n #:	2
2	Co	de:	Resolution I-16 B-202
3	Titl	e:	A Resolution to Have the Retail Price of Drugs Displayed
4			in Direct-to-Consumer Pharmaceutical Advertising
5	Spo	onsor:	Ronald Abramson, MD
6	_		
7	Re	commendation:	
8	Mia	tor operior your reference	a committee recommende that Decelution I 16 D 202 he
9 10			e committee recommends that Resolution I-16 B-202 be dition to read as follows:
11	au	opted as amended by ad	ultion to read as follows.
12	1	RESOLVED That the MI	MS advocate to the applicable Federal agencies
13	••	•	Drug Administration, the Federal Trade Commission,
14			inications Commission) which regulate or influence
15			ertising of prescription drugs that such advertising
16			tate the manufacturer's suggested retail price of those
17		drugs; and, be it further	
18		-	
19	2.		MS request that the AMA advocate to the applicable
20			ding the Food and Drug Administration, the Federal
21		•	the Federal Communications Commission) which
22			rect-to-consumer advertising of prescription drugs that
23			be required to state the <u>manufacturer's suggested</u>
24		retail price of those drug	gs. (<i>D</i>)
25 26	Fie	cal Note:	No Significant Impact
27		ut-of-Pocket Expenses)	No oignineant impact
28	(01		
29	FT	E:	Existing Staff
30		aff Effort to Complete Proj	•
31	\	· · · · · · · · · · · · · · · · · · ·	
32	Yo	ur reference committee he	ard testimony overwhelmingly in support of this resolution.
33	Tes	stimony centered around t	he exorbitant cost of drugs, the exploitation of some
34		-	ith regard to necessary medication, such as EPIPEN, and
35	•	•	ct to consumer advertising which often leads to patients
36		Ū	st recently advertised medication with little knowledge of its
37		• • •	I that due to value-based purchasing it is imperative that
38		•	
	•		ade publically available and transparent. The original
39			lead to a discussion about the prescription drug industry's
40	-		nes, which can vary from one state to another. Based on
41			e committee replaced "retail" with "manufacturer's suggested
42			pend on different pharmacy practices, contract
43	neg	gotiations, or state regulati	ions but will remain consistent nationwide. Therefore, your
44	refe	erence committee recomm	nends that this resolution be adopted as amended.
45			
46	Ho	use Vote:	

1	Item #:	3
2	Code:	Resolution I-16 B-203
3	Title:	Expansion of MassPAT to Enhance the Medication
4		Reconciliation Process
5	Sponsor:	Ronald Newman, MD
6		
7	Recommendation:	
8 9	Mistor spoakor your reference	ce committee recommends that Resolution I-16 B-203 be
9 10	not adopted.	te commute recommends that Resolution 1-10 B-203 be
11	not adopted.	
12	RESOLVED. That the MMS	advocate for the expansion of MassPAT so that
13	•	cations prescribed and dispensed in the
14	Commonwealth is available	e to those who perform medication reconciliation
15	between transitions of care	e. (D)
16		
17	Fiscal Note:	No Significant Impact
18	(Out-of-Pocket Expenses)	
19 20	FTE:	Existing Staff
20	(Staff Effort to Complete Proj	
22		
23	Your reference committee he	eard testimony, both online and in-person, generally in
24		While it was recognized that medication reconciliation can
25		make it easier would be useful, many stated that the
26		ructure as a state-mandated tool has a singular focus and
27		ing controlled substances. Expansion of the use of the
28		viate from the primary purpose and could make tracking
29		cult. Concerns were also raised about having the
30		mation due to the privacy concerns that such a program
31	•	oncern was raised that licensure issues could result from the
32	•	access a list of medications a physician is taking.
33	•	mmittee recommends not adopting this resolution.
33 34	Therefore your reference con	
34 35	House Vote:	

1	Item #:	4
2	Code:	CIT Report I-16 B-1
3	Title:	Proposal to End the Federal Certification of EHRs Program
4	Sponsor:	Committee on Information Technology
5		Glenn Tucker, MD, Chair
6 7 8	Recommendation:	
9	Mister speaker, your referer	nce committee recommends that the recommendations
10		6 B-1 be adopted by addition and deletion to read as
11	follows and the remainder	
12		·
13		ocate to our State and Federal Representatives to end all
14		inancial inducements arising from the use or non-use of
15		rdinator (ONC) Certified EHR Technology. (D)
16		k with appropriate government entities to foster EHR
17		ty, and functionality by modifying the certification
18	process for EHRs to in	nprove patient care. (D)
19		
20	2 That the MMC will area	nurana aur Maaaaahuaatta Fadaral Lasialatara
21 22		ourage our Massachusetts Federal Legislators
22		lizabeth Warren and Edward Markey and Representatives Govern, Niki Tsongas, Joseph P. Kennedy III, Katherine
23 24		like Capuano, Stephen Lynch, and Bill Keating) to
25		end the ONC's EHR certification program, and will ask
26	•	nited States to immediately request that such legislation
27	be introduced. (D)	
28		
29	3-2.That the MMS will enco	ourage the ONC to define HIT standards that can be
30		dors/innovators to exchange medical information
31	between EHRs and oth	er HIT tools. (D)
32		
33		ourage the ONC to maintain a public website where
34		s, and vendors can assess the ability of their EHR (and
35		hange information with other EHRs (and other HIT tools)
36	in accordance with the	e ONC's recommended standards. (D)
37		
38	Fiscal Note:	No Significant Impact
39	(Out-of-Pocket Expense)	
40	FTF.	Eviating Staff
41	FTE:	Existing Staff
42	(Staff Effort to Complete Pro	Jjeci)
43 44	Vour reference committee h	neard significant and mixed testimony on this report both in
45		son recommended adoption only of item one, in order to start
46	•	e medical profession and leave it to the free market. Overall,
47		gely in favor of the intent of the resolution, with differences of
48	opinion regarding which iter	ns were most important.
49		
50	In the case of recommendat	tions one and two, your reference committee heard testimony
51	that expressed an overall se	ense of concern with the language and wording of

1	recommendation one and the specificity of recommendation two. In the case of
2	recommendation one, most felt that it was not accomplishing exactly what was intended
3	and some raised concerns as to what this would mean in light of Medicare Access CHIP
4	Reauthorization Act. An amendment was submitted seeking to replace
5	recommendations one and two with a consolidated recommendation focusing on
6	reforming EHR certification programs, which was intended to bring the resolution more in
7	line with the actual issues it was reportedly seeking to solve. Your reference committee
8	reviewed the suggested amendment and based on the testimony received in support of
9	this language felt that inclusion, with some additional language modifications would be
10	appropriate in order to preserve the intent and capture the flavor of testimony.
11	
12	With regard to recommendations three and four, your reference committee heard overall
13	support for these recommendations, and recommends adopting clauses three and four
14	as they appear in the report.
15	
16	Therefore, in total, your reference committee recommends that this report be adopted as
17	amended.
18	
19	House Vote:

1 2 3	Item #: Code: Title:	5 COL Report I-16 B-2 [A-16 B-202] Telemedicine Reimbursement
3 4 5 6	Sponsor:	Committee on Legislation Hugh Taylor, MD, Chair
7 8 9	Report History:	Resolution A-16 B-202 Original Sponsor: Michael Goldstein, MD
10 11	Recommendation:	
12 13 14 15	1 / 2	mittee recommends that the recommendation -16 B-202] be adopted as amended by addition to r of the report be filed:
16 17 18 19 20 21	the existing telemedicine codes s and physician-to-patient commun and secure email/patient gateway	ate reimbursement for services submitted under uch as telephone consultations, chart reviews, ication including telephone, videoconferencing, communication — as long as such actions are ds <u>and the service is provided in the context of</u> relationship. (D)
22 23 24	Fiscal Note: (Out-of-Pocket Expenses)	No Significant Impact
25 26 27 28	FTE: (Staff Effort to Complete Project)	Existing Staff
29		animous testimony in favor of this report. Testimony
30		already exist and are in use by some commercial
31 32		emedicine. Testimony was largely in support of the for adequate reimbursement of the time physicians
33		er that care is provided in person or via telemedicine.
34		ceived strong favorable testimony, seeking to ensure
35		t would apply to existing physician-patient
36	-	e-time encounters. Some testimony addressed the
37	-	me spent in physician-to-physician consultation
38	•	committee recognized and discussed the importance
39	• • •	beyond the purview of this report and may be best
40		vn. Therefore, your reference committee
41 42	recommends that this report be ado	
43	House Vote:	

1	Item #:	:	6
2	Code:		CSPP Report I-16 B-3
3 4	Title:		Reimbursement for Physician Oversight in Incident to Billing
5 6 7	Spons	or:	Committee on Sustainability of Private Practice Hugh Taylor, MD, Chair
8 9	Recom	nmendation:	
9 10 11 12 13	contair		ce committee recommends that the recommendations 16 B-3 be referred to the Board of Trustees for report
14 15 16 17 18	1.	legislation requiring physician-supervise	etts Medical Society will introduce and support MassHealth to reimburse for services provided by ed advanced practice nurses at the same level as if been provided by the physician. <i>(D</i>)
19 20 21 22 23	2.	for services provide	etts Medical Society encourage all payers to reimburse d by physician-supervised advanced practice nurses at those services had been provided by the physician.
24 25 26	Fiscal (Out-o	Note: f-Pocket Expenses)	No Significant Impact
20 27 28 29	FTE: (Staff I	Effort to Complete Proj	Existing Staff ect)
 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 	genera which provide explora ought phrase explicit assista reimbu be mis physic your cu referen for Rej	ally in favor of the conc should be acknowledg es to a patient. Howev ation and clarification. to more clearly define to have meaning. Se t mention of "advanced ants, might inappropria ursement. Third and fin sconstrued and uninten ian healthcare provide ommittee believes is no nce committee recomm port Back at A-17.	eard testimony both in person and online, which was rept behind this report, that physician supervision has value ed in the reimbursement a team receives for the care it ver, testimony highlighted three issues which require further First, some testimony expressed concern that the report what is meant by "physician-supervised" in order for that cond, other testimony worried that the recommendations' d practice nurses," but not of midwives or physician tely limit the physician oversight for which a team receives hally, testimony focused on the fact that the language could ationally result in the idea that care provided by non- rs is of equal value to that provided by physicians, which of the intent of this report. To resolve these issues, your mends that this report be referred to the Board of Trustees
46	House	Vote:	

1	Item #:	7
2	Code:	Resolution I-16 B-204
3	Title:	Third-Party Payers Contracted Fee Schedule Should Be
4		Based on at Least 100 Percent of the Current and
5		Geographically Appropriate Medicare Fee Schedule at
6		Time of Contracting
7	Sponsor:	David Kieff, MD
8		
9	Recommendation:	
10		
11		ce committee recommends that Resolution I-16 B-204 be
12	adopted as amended by ad	dition and deletion to read as follows:
13		
14		advocate that third-party payer contracted fee
15		<u>less than</u> at least a 100 percent of the current and
16		Medicare fee schedule for the year in which the
17	contract was created. (D)	
18		
19	Fiscal Note:	No Significant Impact
20	(Out-of-Pocket Expenses)	
21		
22	FTE:	Existing Staff
23	(Staff Effort to Complete Proj	ect)
24		
25		eard testimony in person and online in support of the
26		igh online testimony, wanted to be sure that the most
27		le would serve as the basis for health plan payment, as
28		e that they are using the Medicare fee schedule but the
29		ars old. Testimony indicated that there was support for
30	•	ee schedule as a standard from which to discuss payment
31	rates.	
32		and mont from "at locat" to "no loca them" 100 norecent of the
33 34		endment from "at least" to "no less than" 100 percent of the ler to reinforce the point that physicians should receive from
34 35		in the Medicare rate. There was concern raised during
36		f fees to the Medicare standard, and that the words "at
30 37		include "at most." An amendment was proposed in order to
38		reference committee felt that this was in line with the intent
39		<i>n</i> his online testimony. Therefore your reference committee
40	recommends adoption of iter	
40		
42	House Vote:	

1	Item #:	8
2	Code:	Resolution I-16 B-205
3 4	Title:	Timely Response by the Third-Party Payer to the Request for Fee Schedule from Participating Practices
5	Sponsor:	David Kieff, MD
6		
7	Recommendation:	
8		
9		ce committee recommends that Resolution I-16 B-205 be
10	adopted.	
11		
12	•	advocate for and affirm that the third-party payer shall
13		physician practice said practice's fee schedule within
14	48 nours of a written or do	cumented phone request. <i>(D)</i>
15		No Cignificant Impact
16	Fiscal Note:	No Significant Impact
17 10	(Out-of-Pocket Expenses)	
18 19	FTE:	Existing Staff
		•
20 21	(Staff Effort to Complete Proj	
22	Vour reference committee he	pard limited testimony uponimously in support of this
22		eard limited testimony unanimously in support of this t knowing third-party payer fee schedules is important for
23 24		considering whether or not to participate with a particular
24 25		your reference committee recommends adopting this
25 26	resolution.	
20		
27		
27 28	House Vote:	

1	Item #:	9
2	Code:	Resolution I-16 B-206
3 4	Title:	Adding Transparency and Responsiveness to Denied Claims Appeals
5	Sponsor:	David Kieff, MD
6		
7 8	Recommendation:	
9 10	Mister speaker, your reference adopted as amended by de	ce committee recommends that Resolution I-16 B-206 be eletion to read as follows:
11 12 13 14 15 16 17	making a formal reques physician's practice sh	MS advocate for and affirm that within 48 hours of at to third party payers for review of a rejected claim, a all be entitled to speak with a medical professional to ation and reason therefore and to obtain guidance; and,
17 18 19 20 21		MS advocate for and affirm that third-party payers k date on claims appeals submitted by U.S. mail as the be it further <i>(D</i>)
22 23 24 25	may submit claim appe	IMS advocate for and affirm that a physician's practice als to third party payers by any of the following: U.S. ecure fax, or secure email. <i>(D)</i>
25 26	Fiscal Note:	No Significant Impact
27	(Out-of-Pocket Expenses)	No oiginnoant impact
28		
29	FTE:	Existing Staff
30	(Staff Effort to Complete Pro	
31		,,
32	Your reference committee he	eard unanimous testimony, both in person and online, in
33		solved clauses of this resolution to increase transparency
34		appeals of denied claims. Your reference committee further
35		y in favor of deleting the second resolved clause which
36		post mark date of the mailing of an appeal. In addition to
37	•	e committee independently noted that it could take longer for
38		appeal than the forty-eight hours proposed for the payer to
39		efore your reference committee recommends that this
40	resolution be adopted as am	
41		
42	House Vote:	

1	Item #:	10
2	Code:	Resolution I-16 B-207
3	Title:	Independent Surgi-centers Are Safe and Cost Effective
4	Sponsor:	David Kieff, MD
5		
6	Recommendation:	
7		
8	Mister speaker, your reference	ce committee recommends that Resolution I-16 B-207 be
9	referred to the Board of Tru	istees for report back at I-17.
10		
11	•	advocate for and affirm the importance of allowing
12		to operate in Massachusetts and deem current
13		mpediments to this to be barriers to competition and
14	against the value-driven int	erest of patients and physicians. (D)
15		
16	Fiscal Note:	No Significant Impact
17	(Out-of-Pocket Expenses)	
18		
19	FTE: None	Existing Staff
20	(Staff Effort to Complete Proj	ect)
21		
22		ard in-person testimony strongly in favor of this resolution,
23		endent surgery centers by ensuring that the Massachusetts
24		am does not unduly favor hospital-affiliated surgery centers.
25		onvincingly argued that the general description of "current
26	o i o i	pediments to" independent surgery centers operating in
27		r-broad, as not all impediments are necessarily barriers to
28		interests of patients and physicians. Your reference
29		ends that this resolution be referred to the Board of
30	Trustees for report back at I-	17.
31		
32	House Vote:	

1	Item #:	12
2	Code:	Resolution I-16 B-208
3	Title:	Support for Deferred Action for Childhood Arrivals (DACA)-
4		Eligible Health Care Professionals, Current and in Training
5	Sponsors:	Steven Young
6	•	Christie Morgan, MD
7		Annirudh Balachandran
8		Andrew LaFlam
9		Vartan Pahalyants
10		Maximilian Pany
11		Nabil Saleem
12		Lauren Schleimer
13		Caroline Yang
14		Mark Zaki
14 15		Mark Zaki
16	Recommendation:	
17	Recommendation.	
	Mistor apackar, your referen	ce committee recommends that the recommendations
18	1 / 2	
19		B-208 be adopted as amended by addition to read as
20	follows:	
21		laasse kussette Medical Casietu jasus a statement in
22	•	assachusetts Medical Society issue a statement in
23		idents, residents, and fellows training in health care,
24		on for Childhood Arrivals recipients; and be it further
25	(D)	
26		
27		assachusetts Medical Society advocate for <u>the</u>
28		practice of medical students, residents, and fellows in
29		in health care, who are Deferred Action for Childhood
30	Arrivals recipients. (D)	
31		
32	Fiscal Note:	No Significant Impact
33	(Out-of-Pocket Expense)	
34		
35	FTE:	Existing Staff
36	(Staff Effort to Complete Pro	iect)
37	Υ I	, ,
38	Your reference committee he	eard overwhelmingly supportive testimony for this resolution.
39		n resulting from the recent presidential campaign and
40		Id Trump who has declared that he will repeal Deferred
41		(DACA) when he becomes President. This repeal would
42		ents, residents, and fellows currently training in
43		pients of DACA. Many testified that DACA recipients are
44 44	•	ties, and are in the midst of their training and should be
44 45		to return to these under-served communities to provide care,
	· • • •	· · · ·
46		care. Importantly, testimony emphasized that this
47		do with immigration status, but rather allows DACA
48	recipients who are currently	training in Massachusetts to complete their education and
49	recipients who are currently training. Your reference con	training in Massachusetts to complete their education and nmittee received a friendly amendment which the sponsor
49 50	recipients who are currently training. Your reference con and other testimony also sup	training in Massachusetts to complete their education and nmittee received a friendly amendment which the sponsor ported. The reference committee therefore recommends
49 50 51	recipients who are currently training. Your reference con	training in Massachusetts to complete their education and nmittee received a friendly amendment which the sponsor ported. The reference committee therefore recommends
49 50	recipients who are currently training. Your reference con and other testimony also sup	training in Massachusetts to complete their education and nmittee received a friendly amendment which the sponsor ported. The reference committee therefore recommends

Mister speaker, this concludes the report of Reference Committee. My thanks to reference committee members Adarsha Bajracharya, MD, Helen Cajigas, MD, Christopher Garofalo, MD, Steve Kasparian, MD, Mr. Maximilian Pany, and Vincent Smith, MHA, MD, MPH; staff coordinators Kerry Ann Hayon, MHA, Yael Miller, MBA, Jillian Pedrotty, MHA, and Lisa Smith; legal counsel Liz Rover Bailey, Esq.; and all those who testified before the committee.

For the reference committee,

Aimie Zale, MD, Chair

REFERENCE COMMITTEE C: MMS Administration

Item #	Title	Code	Action	Page
1	Reducing Barriers to Participation in MMS House of Delegates Meetings for Members with Children/Families	Resolution I-16 C-101	Adopt	1
2	Ensure Representative Diversity in MMS Leadership Pathways	TFDLP Report I-16 C-1 [I-15 C-3]	Adopt	2
3	MMS Committee and Leadership Representation	CWM Report I-16 C-2	Adopt as Amended	3
4	MMS Leadership Promotion and Governance	CWM Report I-16 C-3	Refer to BOT for Report Back A-17	4
5	Proposed Amendment to the Sunset Policy Procedure	CSP/Officers Report I- 16 C-4	Adopt as Amended	5
6	Special Committee Renewals	BOT Report I-16 C-5	Adopt as Amended	7

1	Item #:	1	
2	Code:	Resolution I-16 C-101	
3	Title:	Reducing Barriers to Participation in MMS House of	
4		Delegates Meetings for Members with Children/Families	
5	Sponsors:	McKinley Glover IV, MD	
6	-	Resident and Fellow Section	
7		Aaron Kithcart, MD, Chair	
8			
9	Recommendation:		
10			
11	Mister speaker, your reference	ce committee recommends that Resolution I-16 C-101 be	
12	adopted.		
13			
14	RESOLVED , That MMS exp	lore mechanisms that would allow MMS members with	
15	children/families to particip	bate during HOD meetings, with report back at A-17. (D)	
16			
17	Fiscal Note:	No Significant Impact	
18	(Out-of-Pocket Expenses)		
19			
20	FTE:	Existing Staff	
21	(Staff Effort to Complete Proj	ect)	
22			
23		eard unanimous support for this resolution. Testimony	
24	, , ,	erent mechanisms to encourage members with	
25	children/families to participate during HOD meetings including childcare, eldercare,		
26		ndly overflow room, and field trips. There was mixed	
27		ne survey is useful to explore the needs of the members as	
28		pshot of their concerns, and other methodologies should be	
29	explored in the report as well		
30			
31	House Vote:		

1	Item #:	2
2	Code:	TFDLP Report I-16 C-1 [I-15 C-3]
3	Title:	Ensure Representative Diversity in MMS
4		Leadership Pathways
5	Sponsor:	Task Force on Ensuring Representative Diversity in
6		MMS Leadership Pathways
7		Nidhi Lal, MD, Chair
8		
9	Report History:	OMSS Report I-15 C-3
10		
11	Recommendation:	
12 13	Mistor speaker, your reference com	nittee recommends that the recommendations
14		[I-15 C-3] be adopted and the remainder of the
15	report be filed.	
16		
17	1. That the Massachusetts Medic	al Society create a Minority Affairs Section in
18		sented groups and communities across the
19		Id be entitled to one delegate in the House of
20	Delegates, and the delegate sh	nall be elected by the section. (D)
21		
22	2. That the MMS obtain race and	ethnicity data for MMS members by utilizing all
23	available sources, including th	hird-party vendors, in order to understand the
24	current composition of the MM	IS membership, and assist in the development of
25	future goals. (D)	
26		
27	Fiscal Note:	Annual Expense of \$5,000
28	(Out-of-Pocket Expenses)	(Beginning FY18)
29		One-Time Expense of \$9,000
30		
31	FTE:	Existing Staff
32	(Staff Effort to Complete Project)	
33		
34		timony both online and in person strongly in favor of
35		ified in opposition to creating a Minority Affairs
36		a formal section. There was overwhelming support
37	•	ity data. However, some members testified on the
38	•	nfidential data given the potentially sensitive nature
39	of the data collected.	
40		
41		t recommendation 1 will be referred to the
42	•	the House of Delegates on the necessary bylaws
43		
44	changes.	

45 House Vote: _____

1	Item #	3
2	Code:	CWM Report I-16 C-2
3	Title:	MMS Committee and Leadership Representation
4	Sponsor:	Committee on Women in Medicine
5		Helen Cajigas, MD, Chair
6		
7	Recommendation:	
8		
9		nmittee recommends that the recommendation
10	•	be adopted as amended by addition and deletion
11	to read as follows and the remain	nder of the report be filed:
12		
13		Society commit to promote representation in its
14	-	reflects the Society's membership diversity,
15	demographics, and gender. (D)	
16		
17	Fiscal Note:	No Significant Impact
18	(Out-of-Pocket Expenses)	
19	ete	
20	FTE:	Existing Staff
21	(Staff Effort to Complete Project)	
22	Vour reference committee beerd to	atima ny una nina yaky in fayar of thia
23		stimony unanimously in favor of this
24		nony favored replacing the words "commit to" with
25	"promote" in part to ensure that que	das would not be required.
26 27	House Vote:	
//		

1	Item #:	4
2	Code:	CWM Report I-16 C-3
3	Title:	MMS Leadership Promotion and Governance
4	Sponsor:	Committee on Women in Medicine
5		Helen Cajigas, MD, Chair
6		JO / /
7 8	Recommendation:	
9 10 11		mittee recommends that the recommendations be referred to the Board of Trustees for report
12 13 14 15		cal Society facilitate increased leadership es by limiting a committee member's service as rs (not sum total). (D)
16	chair to three consecutive yea	
17 18	2. That a Massachusetts Medical be limited to not more than on	Society member's leadership service as chair e committee concurrently. <i>(D)</i>
19 20 21 22 23 24	structure for leadership appoir Forces (Chair), and appointme there may be opportunities to	al Society review the present governance ntments to committees (Chair/Vice Chair), Task ents to special committees to ascertain whether consider improvements in regard to process, sentation of best practices. <i>(D)</i>
25 26	Fiscal Note:	No Significant Impact
27	(Out-of-Pocket Expenses)	5
28		
29	FTE:	Existing Staff
30	(Staff Effort to Complete Project)	3 3 3 3
31		
32	Your reference committee heard tes	timony both online and in person unanimously in
33		owever, most of the testimony questioned the
34	possibility of unintended consequent	ces of recommendations 1 and 2. For example,
35		n the steep learning curve on chairing some
36	committees, such as the Committee	on Finance or the Committee on Legislation, a
37	three-year term limit was too brief ar	nd should be extended to five or even six years.
38		npact of limiting leadership service to not more than
39		uld limit the number of potential candidates for
40		ere with leadership pathways for diverse groups of
41		d that only appointed chair positions should be
42		positions unchanged. Given that recommendations
43		ecificity and that testimony outlined many of the
44	•	mendations, your reference committee recommends
45	that the report be referred to the BO	I with a report back at A-17.
46		
47	House Vote:	

1	Item #:	5
2	Code:	CSP/Officers Report I-16 C-4
3	Title:	Proposed Amendment to the Sunset Policy
4		Procedure
5	Sponsors:	Committee on Strategic Planning
6		Henry Dorkin, MD, Chair
7		MMS Presidential Officers:
8		James Gessner, MD
9		Henry Dorkin, MD
10		Alain Chaoui, MD
11		
12	Recommendation:	
13		
14	Mister speaker, your reference comr	nittee recommends that the recommendation
15		6 C-4 be adopted as amended by addition to
16	read as follows and the remainder	
17		
18	That the Massachusetts Medical S	ociety amend the Procedures of the
19	House of Delegates to read as foll	•
20	nouse of Delegates to read as roll	UN 3.
20	19. SUNSET POLICY	
22		von voor time herizen shell eviet fer ell
22		ven-year time horizon shall exist for all y policy positions and statements established
23 24		es. Each adopted resolve or recommendation
24 25		ered individually with regard to the sunsetting
26		echanism, a policy will cease to be viable unless
20 27		o re-establish said policy. Any action of the
28		ig policy shall reset the sunset "clock," making
20 29		seven years from the date of its reaffirmation.
30		nodifies an existing policy shall reset the sunset
31		d or modified policy viable for seven years from
32	the date of its adoption.	a of modified policy viable for seven years from
33	the date of its adoption.	
34	Directives adopted by the Hou	se which contain time-limited specifics;
35		ees, or other special or ad hoc entities; and
36		dures of the House of Delegates or the Bylaws
37		en-year sunset mechanism and shall sunset
38		n of the directive or document update.
39	automationly at the completion	
40	Review/Report Process	
41		ers and staff to the appropriate standing
42		consultation with appropriate special
43		ommend whether to reaffirm, sunset, reaffirm for
44		and provide recommendations to the MMS
45		eview and submission to the House of Delegates.
46		
47	Minor Amendments that Maint	ain the Original Intent of the Policy
48		propose amendments to any policy that
49		the policy. Such policy amendments may only
50		the House of Delegates. If a proposed policy

1 2 3 4 5	amendment is not adopted, the original policy will be reaffirmed for one year and referred to the appropriate committee(s) for further analysis and potential submission of a new policy recommendation. Such items must be reported back to the House of Delegates within one year.
6 7 8 9 10 11	The reviewing committees/MMS sections and presidential officers shall prepare a single report recommending policy reaffirmation, policy sunset, policy amendment, and policy reaffirmation for one year pending submission of an updated policy for transmittal to the House on an annual basis, which shall be assigned to a single reference committee for consideration.
12 13 14	A consent calendar format shall be used by the House in considering the policies contained in the report.
15 16 17 18 20 21 22 23 24 25 26 27 28 29 30 31 32	Policies That Require New Policy Recommendations If it is determined by the reviewing committee/MMS section(s) that a policy requires a completely new policy recommendation, a new policy recommendation should be submitted for the current Annual Meeting of the House of Delegates by the resolution/report deadline. Such resolutions/reports will not be accepted as late-filed items. If the updated policy recommendation is not submitted for the current Annual Meeting, then such policy will be recommended to be reaffirmed for one year. Following House action the Board of Trustees, and/or any committee(s) designated by the Board of Trustees, will be asked to consider submitting the new policy recommendation. Upon submission and adoption of a new policy recommendation is not adopted; the old policy will automatically be sunset. If the new policy recommendation is not adopted; the old policy will automatically be sunset. If new policy is referred, the old policy will be maintained until report back within a one year period. If no new recommendation is adopted within one year, the policy will automatically sunset. (D)
33 34 35	Fiscal Note: No Significant Impact (Out-of-Pocket Expenses)
36 37 38	FTE: Existing Staff (Staff Effort to Complete Project)
 39 40 41 42 43 44 45 46 47 48 	Your reference committee heard testimony predominantly in favor of this report noting that it streamlines the existing committee renewal process and provides CSP with additional time to focus on strategic planning. Some argued that the collective wisdom of the CSP would be lost in making this change, however, others testified that sunset policies will continue to go to the HOD for a vote. The question of who assigns the policies to the appropriate committees under the proposed recommendations was a recurring concern of those testifying. The President clarified that the officers and the staff would assign the policies. Hence, your reference committee made the proposed amendment to reflect this clarification.
49	House Vote:

1	Item #:	6
2	Code:	BOT Report I-16 C-5
3	Title:	Special Committee Renewals
4	Sponsor:	Board of Trustees
5		James Gessner, MD, Chair
6		
7	Recommendation:	
8		
9	Mister speaker, vour referen	ice committee recommends that the recommendation
10		6 C-5 be adopted as amended by addition to read as
11	follows and the remainder	
12		
13	1. That the House of Deleg	ates support the renewal of the following Committees:
14		ory, Information Technology, LGBT Matters, Maternal
15		Senior Volunteer Physicians, Student Health and Sports
16		rvention and Prevention, and Young Physicians. (D)
17		
18	2. That the MMS study cor	nmittee meeting attendance. (D)
19		
20	3. That the MMS report bac	ck at A-17 with recommendations for addressing
21		s and other processes to improve committee meeting
22	attendance. (D)	<u> </u>
23	<u>`</u>	
24	Fiscal Note:	Average Annual Expense per Committee
25	(Out-of-Pocket Expenses):	(for 3 years beginning FY18):
26	(,	\$3,000 per committee, for a total of \$27,000
27		+ - ,
28	FTE:	Existing Staff
29	(Staff Effort to Complete Pro	
30		J = = - j
31	Your reference committee re	eceived several proposed recommendations associated with
32		ee meetings. The testimony from the President-elect in
33		rs' commitment to monitoring committee members'
34		nsiderations, your reference committee incorporated revised
35		ndations in an effort to address the concerns, preserving the
		, i
36		nendations.
36 37	original intent of the recomn	nendations.

Mister speaker, this concludes the report of Reference Committee C. My thanks to reference committee members Essam Al-Ansari, MD, Nick Argy, MD, JD, Mr. Patrick Lowe, Mawya Shocair, MD, Mr. Steven Young, and Ms. Marguerite Youngren; Staff coordinators Therese Fitzgerald, PhD; and Brett Bauer; and legal counsel, Paul Auffermann, Esq.

For the reference committee,

Kathryn Hughes, MD, Chair